Cygnus Technologies, the leading assay and services provider for the detection and characterization of impurities in biopharmaceuticals, announced today that it has selected DBA Italia S.r.l. to distribute its products in Italy. DBA Italia has a 34-year track record, serving customers in biomedical research, immunology, biochemistry, molecular biology, microbiology, vaccine development and veterinary medicine. The Italian company also has an existing successful relationship with Vector Laboratories which, along with Cygnus Technologies, is owned by Maravai LifeSciences.
"We are very excited to be working with DBA Italia, as the company has a strong track record for distribution, sales and service to its customers in Italy," said Ravi Vinayak, Ph.D., general manager of global channel distribution for Maravai LifeSciences. "The company is well respected in academia as well as the biotech and pharmaceutical industries. We look forward to continuing our growth in Italy with the help of DBA Italia."
Cygnus Technologies develops, manufactures and markets assay kits and related services that enable pharmaceutical and biotech companies to detect and identify host cell impurities in biotherapeutics, an important step in regulatory approval and quality control processes. With products, services and expert advice, Cygnus helps biopharmaceutical companies move new therapeutics more quickly through the development and approval stages to market. With headquarters in Southport, N.C., Cygnus Technologies serves customers worldwide through a global distributor network. A privately held company, Cygnus Technologies was acquired by Maravai LifeSciences in 2016.
David Weber, Chief Commercial Officer